StockMacro
Menu

Scynexis

$2.38 -56% in 6 monthsMarket cap $23.7M

SCYX on XNAS, Health Care, SCYNEXIS, Inc., job postings

Measures activity, not value. Not investment advice.

First federal award of $18.5M came as shares fell 57% in 12 months.

  • GoodRevenue rose 544% to $18.9M over the last 12 months
  • WatchTwo director or officer changes in the last 90 days

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Industry
Pharmaceutical preparations (Health Care)
Employees
29
Website
scynexis.com
Listed
Nasdaq, US
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $8.5M.
Quarter to 31 Dec 2021: revenue –, net income -$29.2MQuarter to 31 Mar 2022: revenue $687K, net income -$5.5MQuarter to 31 Mar 2022: revenue $687K, net income -$5.5MQuarter to 30 Jun 2022: revenue $1.3M, net income -$13.3MQuarter to 30 Jun 2022: revenue $1.3M, net income -$13.3MQuarter to 30 Sep 2022: revenue $1.6M, net income -$29.6MQuarter to 30 Sep 2022: revenue $1.6M, net income -$29.6MQuarter to 31 Dec 2022: revenue $1.5M, net income -$14.4MQuarter to 31 Dec 2022: revenue $1.5M, net income -$14.4MQuarter to 31 Mar 2023: revenue $1.1M, net income -$33.9MQuarter to 31 Mar 2023: revenue $1.1M, net income -$33.9MQuarter to 30 Jun 2023: revenue $131.5M, net income $122.3MQuarter to 30 Jun 2023: revenue $131.5M, net income $122.3MQuarter to 30 Sep 2023: revenue $1.8M, net income -$1.8MQuarter to 30 Sep 2023: revenue $1.8M, net income -$1.8MQuarter to 31 Dec 2023: revenue $5.8M, net income -$19.6MQuarter to 31 Dec 2023: revenue $5.8M, net income -$19.6MQuarter to 31 Mar 2024: revenue $1.4M, net income $411KQuarter to 31 Mar 2024: revenue $1.4M, net income $411KQuarter to 30 Jun 2024: revenue $736K, net income -$14.5MQuarter to 30 Jun 2024: revenue $736K, net income -$14.5MQuarter to 30 Sep 2024: revenue $660K, net income -$2.8MQuarter to 30 Sep 2024: revenue $660K, net income -$2.8MQuarter to 31 Dec 2024: revenue $977K, net income -$4.4MQuarter to 31 Dec 2024: revenue $977K, net income -$4.4MQuarter to 31 Mar 2025: revenue $257K, net income -$5.4MQuarter to 31 Mar 2025: revenue $257K, net income -$5.4MQuarter to 30 Jun 2025: revenue $1.4M, net income -$6.9MQuarter to 30 Jun 2025: revenue $1.4M, net income -$6.9MQuarter to 30 Sep 2025: revenue $334K, net income -$8.6MQuarter to 30 Sep 2025: revenue $334K, net income -$8.6MQuarter to 31 Dec 2025: revenue $18.6M, net income $12.3MQuarter to 31 Dec 2025: revenue $18.6M, net income $12.3MQuarter to 31 Mar 2026: revenue $0, net income -$21.3MQuarter to 31 Mar 2026: revenue $0, net income -$21.3MQuarter to 30 Jun 2026: revenue $235K, net income $7.4MQuarter to 30 Jun 2026: revenue $235K, net income $7.4MQuarter to 30 Sep 2026: revenue $0, net income -$8.5MQuarter to 30 Sep 2026: revenue $0, net income -$8.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $131.5M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$8.5M
30 Jun 2026$235K$7.4M
31 Mar 2026$0-$21.3M
31 Dec 2025$18.6M$12.3M
30 Sep 2025$334K-$8.6M
30 Jun 2025$1.4M-$6.9M
31 Mar 2025$257K-$5.4M
31 Dec 2024$977K-$4.4M
30 Sep 2024$660K-$2.8M
30 Jun 2024$736K-$14.5M
31 Mar 2024$1.4M$411K
31 Dec 2023$5.8M-$19.6M
30 Sep 2023$1.8M-$1.8M
30 Jun 2023$131.5M$122.3M
31 Mar 2023$1.1M-$33.9M
31 Dec 2022$1.5M-$14.4M
30 Sep 2022$1.6M-$29.6M
30 Jun 2022$1.3M-$13.3M
31 Mar 2022$687K-$5.5M
31 Dec 2021–-$29.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $18.9M $2.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +544% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$10.1M -$25.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -127% – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -53.5% -863% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -21.2% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $63.2M $37.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.93
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.3 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.40 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
ScynexisSCYX (this company) $23.7Mloss1.3+544%-53.5%
ABVC BioPharmaABVC $23.4Mloss–––
Incannex HealthcareIXHL $23.3Mloss–––
Rockwell MedicalRMTI $23.1Mloss0.32-4.0%-7.8%
CervoMedCRVO $22.1Mlossover 999-100%–
Briacell TherapeuticsBCTX $26.7Mloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+7.9%

41 13F filers vs 38

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

47%

4.7M shares held by 13F filers (30 Sep 2026) of 10.0M outstanding (1 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

4.5%

450K shares sold short (30 Oct 2026) of 10.0M outstanding (1 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.5

450K shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+7.1%

421K shares sold short in the report before, 450K on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

38%

38% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

1

1 article in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

1 article in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Federal obligations $18.5M
  • First federal award $18.5M, first

Price $2.38 on 20 Nov 2026, -57% over 12 months (12-month range $2.38 to $8.88)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: $0).
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $0 in the latest quarter.
Institutional holders (13F filers). 41 13F filers reported holding it in the latest 13F quarter, -4.7% on a year earlier.
Federal obligations. Federal obligations: $18.5M published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
6 Oct 2026Sharp changeFederal obligations jump: federal obligations jump, 18.5M vs usual 0 in the same month of earlier years (2026-09-01..2026-09-30)
1 Oct 2026Sharp changeFirst federal award: first federal award: SCYNEXIS INC: new Department of Health and Human Services contract 75A50126C00007 ($18,454,788)
22 Sep 20268-K and other filingsDirector or officer change
10 Sep 20268-K and other filingsDirector or officer change
10 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Jun 2026Sharp changeShort interest spike: short interest spike, 2.6M vs usual 1.1M (2026-05-29); 4.0x the same period a year earlier
2 Jun 2026Sharp changeShort interest spike: short interest spike, 2.3M vs usual 1.1M (2026-05-15); 3.5x the same period a year earlier
12 May 2026Sharp changeShort interest spike: short interest spike, 2.1M vs usual 1.1M (2026-04-30); 3.3x the same period a year earlier
20 Apr 20268-K and other filingsDirector or officer change
20 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
31 Mar 20268-K and other filingsCompleted an acquisition or asset sale
5 Mar 2026Sharp changeQuarterly revenue change: quarterly revenue change, 18.6M vs usual 856K (2025-12-31); 19.1x the same period a year earlier
2 Dec 2025Sharp changeShort interest spike: short interest spike, 1.2M vs usual 693K (2025-11-14); 1.5x the same period a year earlier
26 Jun 20258-K and other filingsDelisting notice or listing transfer
15 Aug 2023Sharp changeQuarterly revenue change: quarterly revenue change, 131.5M vs usual 1.2M (2023-06-30); 99.4x the same period a year earlier
23 Jun 20238-K and other filingsA major agreement ended
13 Jun 2023Sharp changeShort interest spike: short interest spike, 1.8M vs usual 1.0M (2023-05-31); 1.5x the same period a year earlier
16 May 2023Sharp changeShort interest spike: short interest spike, 1.8M vs usual 1.0M (2023-04-28); 1.4x the same period a year earlier
2 May 2023Sharp changeShort interest spike: short interest spike, 3.0M vs usual 1.0M (2023-04-14); 2.2x the same period a year earlier
18 Apr 2023Sharp changeShort interest spike: short interest spike, 2.3M vs usual 1.0M (2023-03-31); 1.6x the same period a year earlier
20 Oct 20228-K and other filingsDirector or officer change
20 Oct 20228-K and other filingsA major agreement ended
20 Oct 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Feb 20228-K and other filingsDirector or officer change
8 Feb 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Apr 2022: $236K published
Month from 1 Sep 2024: $27K published
Month from 1 Apr 2026: $0 published
Revenue per quarter
Quarter ended 31 Mar 2022: $687K, -94% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $1.3M; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $1.6M, +202% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $1.5M; public on 1 Apr 2023
Quarter ended 31 Mar 2023: $1.1M, +64% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $131.5M, +9836% on a year earlier; public on 15 Aug 2023
Quarter ended 30 Sep 2023: $1.8M, +13% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $5.8M, +280% on a year earlier; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $1.4M, +22% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $736K, -99% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $660K, -63% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $977K, -83% on a year earlier; public on 13 Mar 2025
Quarter ended 31 Mar 2025: $257K, -81% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $1.4M, +85% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $334K, -49% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $18.6M, +1808% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $0, -100% on a year earlier; public on 12 May 2026
Quarter ended 30 Jun 2026: $235K, -83% on a year earlier; public on 11 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $0; public on 30 Mar 2022
Institutional holders (13F filers)
31 Dec 2021 report: 42; public on 14 Feb 2022
31 Mar 2022 report: 46; public on 16 May 2022
30 Jun 2022 report: 41; public on 15 Aug 2022
30 Sep 2022 report: 43; public on 14 Nov 2022
31 Dec 2022 report: 40; public on 14 Feb 2023
31 Mar 2023 report: 52; public on 15 May 2023
30 Jun 2023 report: 50; public on 14 Aug 2023
30 Sep 2023 report: 56; public on 14 Nov 2023
31 Dec 2023 report: 52; public on 14 Feb 2024
31 Mar 2024 report: 55; public on 15 May 2024
30 Jun 2024 report: 51; public on 14 Aug 2024
30 Sep 2024 report: 44; public on 14 Nov 2024
31 Dec 2024 report: 49; public on 14 Feb 2025
31 Mar 2025 report: 39; public on 15 May 2025
30 Jun 2025 report: 38; public on 14 Aug 2025
30 Sep 2025 report: 43; public on 14 Nov 2025
31 Dec 2025 report: 38; public on 17 Feb 2026
31 Mar 2026 report: 46; public on 15 May 2026
30 Jun 2026 report: 38; public on 14 Aug 2026
30 Sep 2026 report: 41; public on 16 Nov 2026
Federal obligations
Month from 1 Oct 2026: $18.5M published

What is unusual now

  • Made public in the last 90 days: it booked $18.5M in federal contract and grant obligations in September 2026, against none in the same month last year; it also won its first federal award in our data, a $18.5M Department of Health and Human Services contract.
  • Federal obligations jump: booked $18.5M in federal contract and grant obligations in September 2026, against none in the same month last year Public on 1 Oct 2026.
  • Short interest spike: had 2.6M shares sold short in the 29 May 2026 report, 4.0× the same report last year Public on 10 Jun 2026.
  • Insider net buying (open market): Insiders bought a net $0 in the last 12 months (the 12 months before: $0).

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 51 insider trades

No trades in the last 90 days; the latest was filed 2 Apr 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
2 Apr 2026Gonzalez David AnguloChief Executive OfficerBuy108,695Not filedNot filedForm 4
16 Sep 2024Gonzalez David AnguloChief Executive OfficerBuy20,000$1.37$27KForm 4
28 Apr 2022Marco TagliettiChief Executive OfficerBuy75,000$3.00$225KForm 4
28 Apr 2022Scott SukenickGeneral CounselBuy3,500$3.00$10KForm 4
26 Jan 2021Perceptive Life Sciences Master Fund Ltd and 2 others10% ownerSell599,000$7.86$4.7MForm 4
23 Dec 2020Scott SukenickGeneral CounselBuy1,600$6.25$10KForm 4
23 Dec 2020Guy MacdonaldDirectorBuy8,000$6.25$50KForm 4
23 Dec 2020Gonzalez David AnguloChief Medical OfficerBuy1,600$6.25$10KForm 4

41 institutions reported shares at the end of Q3 2026, 47% of the shares outstanding; 7 opened a position, 5 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Great Point Partners LLC944K9.49%$4.7MNo change
Adage Capital Partners GP, L.L.C.543K5.46%$2.7MNo change
Propel Bio Management, LLC541K5.44%$2.7M-2,004-0.4%
Squadron Capital Management LLC515K5.17%$2.5M-242K-32%
Vanguard Capital Management LLC419K4.21%$2.1M+123K+41%
Woodline Partners LP379K3.81%$1.9M-8,547-2.2%
Kingdon Capital Management, L.L.C.248K2.49%$1.2MNo change
Avidity Partners Management LP154K1.54%$759K-107K-41%
DAFNA Capital Management LLC136K1.37%$671KNo change
Geode Capital Management, LLC121K1.21%$596K+38K+47%

Federal contracts

All 1 federal contracts

1 new award in 12 months, $18.5M obligated when signed. New awards only; later changes to an award are not listed.

SignedAgencyAmountWhat forSource
25 Sep 2026Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response$18.5Mup to $213.9MADVANCE THE DEVELOPMENT OF SCY-247, A NOVEL ANTIFUNGAL CURRENTLY IN PHASE 1 CLINICAL TRIALS, FOR THE TREATMENT OF INVASIVE CANDIDIASIS AND PROPHYLAXIS OF INVASIVE FUNGAL DISEASE AS ORAL AND IC FORMULAUSAspending

Company events

All 36 company events

In 12 months: 3 major agreements, 3 director or officer changes, 1 completed deal. Results releases and routine reports are left out.

FiledWhat happenedSource
28 Sep 2026Signed a major agreement8-K
22 Sep 2026Director or officer change8-K
10 Sep 2026Director or officer change8-K
20 Apr 2026Director or officer change8-K
31 Mar 2026Signed a major agreement; Completed an acquisition or asset sale8-K
31 Mar 2026Signed a major agreementSame filing: sold shares privately8-K
15 Oct 2025Signed a major agreement8-K
26 Jun 2025Delisting notice or listing transfer8-K
Timeline

Timeline

Changes and notable records, by the date each became public

  1. 1 Oct 2026Government contracts change

    booked $18.5M in federal contract and grant obligations in September 2026, against none in the same month last year.

    See the evidence
    This period
    $18.5M (September 2026)
    Normal month (median of 5 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +18.5
    Same month last year
    $0
    History used
    6,698 days
    2021-09-01: $02022-09-01: $02023-09-01: $02024-09-01: $02025-09-01: $02026-09-01: $18.5M
    September 20265 earlier monthsnormal: $0

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least $5.0M.

    Check it at the source: USAspending.gov award search.

  2. 1 Oct 2026Government contracts change

    won its first federal award in our data, a $18.5M Department of Health and Human Services contract.

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2007
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  3. 1 Oct 2026Government contracts record

    SCYNEXIS INC: new Department of Health and Human Services contract 75A50126C00007 ($18.5M) (dated 25 Sep 2026)

  4. 22 Sep 2026Filings record

    Director or officer change

  5. 10 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 10 Sep 2026Filings record

    Director or officer change

  7. 10 Jun 2026Short interest and volume change

    had 2.6M shares sold short in the 29 May 2026 report, 4.0× the same report last year.

    Same report last year: 642K; its normal report is 1.1M.

    See the evidence
    This period
    2.6M (the 29 May 2026 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    122K
    How far from its usual level
    +8.1
    Same report last year
    642K
    History used
    3,073 days
    2025-05-30: 642K2025-06-13: 623K2025-06-30: 606K2025-07-15: 595K2025-07-31: 519K2025-08-15: 538K2025-08-29: 496K2025-09-15: 674K2025-09-30: 960K2025-10-15: 1.1M2025-10-31: 1.1M2025-11-14: 1.2M2025-11-28: 1.2M2025-12-15: 1.2M2025-12-31: 1.1M2026-01-15: 1.1M2026-01-30: 1.1M2026-02-13: 1.1M2026-02-27: 1.2M2026-03-13: 1.2M2026-03-31: 1.2M2026-04-15: 1.2M2026-04-30: 2.1M2026-05-15: 2.3M2026-05-29: 2.6M
    the 29 May 2026 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  8. 28 May 2026Short interest and volume change

    had 2.3M shares sold short in the 15 May 2026 report, 3.5× the same report last year.

    Same report last year: 641K; its normal report is 1.1M.

    See the evidence
    This period
    2.3M (the 15 May 2026 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    132K
    How far from its usual level
    +6.0
    Same report last year
    641K
    History used
    3,059 days
    2025-05-15: 641K2025-05-30: 642K2025-06-13: 623K2025-06-30: 606K2025-07-15: 595K2025-07-31: 519K2025-08-15: 538K2025-08-29: 496K2025-09-15: 674K2025-09-30: 960K2025-10-15: 1.1M2025-10-31: 1.1M2025-11-14: 1.2M2025-11-28: 1.2M2025-12-15: 1.2M2025-12-31: 1.1M2026-01-15: 1.1M2026-01-30: 1.1M2026-02-13: 1.1M2026-02-27: 1.2M2026-03-13: 1.2M2026-03-31: 1.2M2026-04-15: 1.2M2026-04-30: 2.1M2026-05-15: 2.3M
    the 15 May 2026 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 12 May 2026Short interest and volume change

    had 2.1M shares sold short in the 30 Apr 2026 report, 3.3× the same report last year.

    Same report last year: 641K; its normal report is 1.1M.

    See the evidence
    This period
    2.1M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    1.1M
    Typical spread (median absolute deviation)
    137K
    How far from its usual level
    +5.0
    Same report last year
    641K
    History used
    3,044 days
    2025-04-30: 641K2025-05-15: 641K2025-05-30: 642K2025-06-13: 623K2025-06-30: 606K2025-07-15: 595K2025-07-31: 519K2025-08-15: 538K2025-08-29: 496K2025-09-15: 674K2025-09-30: 960K2025-10-15: 1.1M2025-10-31: 1.1M2025-11-14: 1.2M2025-11-28: 1.2M2025-12-15: 1.2M2025-12-31: 1.1M2026-01-15: 1.1M2026-01-30: 1.1M2026-02-13: 1.1M2026-02-27: 1.2M2026-03-13: 1.2M2026-03-31: 1.2M2026-04-15: 1.2M2026-04-30: 2.1M
    the 30 Apr 2026 report24 earlier reportsnormal: 1.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 20 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 20 Apr 2026Filings record

    Director or officer change

  12. 3 Apr 2026Insiders record

    Angulo Gonzalez David (Chief Executive Officer) bought 108,695 shares of SCYX (dated 2 Apr 2026)

  13. 31 Mar 2026Filings record

    Completed an acquisition or asset sale

  14. 5 Mar 2026Financials change

    reported revenue of $18.6M for the quarter ended 31 Dec 2025, 19× the same quarter last year.

    Same quarter last year: $977K; its normal quarter is $856K.

    See the evidence
    This period
    $18.6M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $856K
    Typical spread (median absolute deviation)
    $512K
    How far from its usual level
    +17.8
    Same quarter last year
    $977K
    History used
    3,562 days
    2023-12-31: $5.8M2024-03-31: $1.4M2024-06-30: $736K2024-09-30: $660K2024-12-31: $977K2025-03-31: $257K2025-06-30: $1.4M2025-09-30: $334K2025-12-31: $18.6M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $856K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 26 Nov 2025Short interest and volume change

    had 1.2M shares sold short in the 14 Nov 2025 report, 1.5× the same report last year.

    Same report last year: 838K; its normal report is 693K.

    See the evidence
    This period
    1.2M (the 14 Nov 2025 report)
    Normal report (median of 24 earlier)
    693K
    Typical spread (median absolute deviation)
    100K
    How far from its usual level
    +3.6
    Same report last year
    838K
    History used
    2,877 days
    2024-11-15: 838K2024-11-29: 795K2024-12-13: 679K2024-12-31: 814K2025-01-15: 845K2025-01-31: 830K2025-02-14: 841K2025-02-28: 756K2025-03-14: 695K2025-03-31: 747K2025-04-15: 691K2025-04-30: 641K2025-05-15: 641K2025-05-30: 642K2025-06-13: 623K2025-06-30: 606K2025-07-15: 595K2025-07-31: 519K2025-08-15: 538K2025-08-29: 496K2025-09-15: 674K2025-09-30: 960K2025-10-15: 1.1M2025-10-31: 1.1M2025-11-14: 1.2M
    the 14 Nov 2025 report24 earlier reportsnormal: 693K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  16. 26 Jun 2025Filings record

    Delisting notice or listing transfer

  17. 17 Sep 2024Insiders record

    Angulo Gonzalez David (Chief Executive Officer) bought 20,000 shares of SCYX ($27,400) (dated 16 Sep 2024)

  18. 15 Aug 2023Financials change

    reported revenue of $131.5M for the quarter ended 30 Jun 2023, 99× the same quarter last year.

    Same quarter last year: $1.3M; its normal quarter is $1.2M.

    See the evidence
    This period
    $131.5M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $1.2M
    Typical spread (median absolute deviation)
    $435K
    How far from its usual level
    +130.2
    Same quarter last year
    $1.3M
    History used
    3,743 days
    2021-03-31: $12.1M2021-06-30: $02021-09-30: $516K2022-03-31: $687K2022-06-30: $1.3M2022-09-30: $1.6M2022-12-31: $1.5M2023-03-31: $1.1M2023-06-30: $131.5M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $1.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  19. 23 Jun 2023Filings record

    A major agreement ended

  20. 10 Jun 2023Short interest and volume change

    had 1.8M shares sold short in the 31 May 2023 report, 1.5× the same report last year.

    Same report last year: 1.2M; its normal report is 1.0M.

    See the evidence
    This period
    1.8M (the 31 May 2023 report)
    Normal report (median of 24 earlier)
    1.0M
    Typical spread (median absolute deviation)
    129K
    How far from its usual level
    +3.8
    Same report last year
    1.2M
    History used
    1,979 days
    2022-05-31: 1.2M2022-06-15: 1.0M2022-06-30: 1.1M2022-07-15: 1.0M2022-07-29: 1.1M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 991K2022-09-30: 1.2M2022-10-14: 1.0M2022-10-31: 1.1M2022-11-15: 1.0M2022-11-30: 1.0M2022-12-15: 956K2022-12-30: 930K2023-01-13: 879K2023-01-31: 802K2023-02-15: 783K2023-02-28: 767K2023-03-15: 781K2023-03-31: 2.3M2023-04-14: 3.0M2023-04-28: 1.8M2023-05-15: 1.7M2023-05-31: 1.8M
    the 31 May 2023 report24 earlier reportsnormal: 1.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 10 May 2023Short interest and volume change

    had 1.8M shares sold short in the 28 Apr 2023 report, 1.4× the same report last year.

    Same report last year: 1.2M; its normal report is 1.0M.

    See the evidence
    This period
    1.8M (the 28 Apr 2023 report)
    Normal report (median of 24 earlier)
    1.0M
    Typical spread (median absolute deviation)
    129K
    How far from its usual level
    +3.9
    Same report last year
    1.2M
    History used
    1,946 days
    2022-04-29: 1.2M2022-05-13: 1.5M2022-05-31: 1.2M2022-06-15: 1.0M2022-06-30: 1.1M2022-07-15: 1.0M2022-07-29: 1.1M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 991K2022-09-30: 1.2M2022-10-14: 1.0M2022-10-31: 1.1M2022-11-15: 1.0M2022-11-30: 1.0M2022-12-15: 956K2022-12-30: 930K2023-01-13: 879K2023-01-31: 802K2023-02-15: 783K2023-02-28: 767K2023-03-15: 781K2023-03-31: 2.3M2023-04-14: 3.0M2023-04-28: 1.8M
    the 28 Apr 2023 report24 earlier reportsnormal: 1.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 26 Apr 2023Short interest and volume change

    had 3.0M shares sold short in the 14 Apr 2023 report, 2.2× the same report last year.

    Same report last year: 1.4M; its normal report is 1.0M.

    See the evidence
    This period
    3.0M (the 14 Apr 2023 report)
    Normal report (median of 24 earlier)
    1.0M
    Typical spread (median absolute deviation)
    129K
    How far from its usual level
    +10.4
    Same report last year
    1.4M
    History used
    1,932 days
    2022-04-14: 1.4M2022-04-29: 1.2M2022-05-13: 1.5M2022-05-31: 1.2M2022-06-15: 1.0M2022-06-30: 1.1M2022-07-15: 1.0M2022-07-29: 1.1M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 991K2022-09-30: 1.2M2022-10-14: 1.0M2022-10-31: 1.1M2022-11-15: 1.0M2022-11-30: 1.0M2022-12-15: 956K2022-12-30: 930K2023-01-13: 879K2023-01-31: 802K2023-02-15: 783K2023-02-28: 767K2023-03-15: 781K2023-03-31: 2.3M2023-04-14: 3.0M
    the 14 Apr 2023 report24 earlier reportsnormal: 1.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  23. 13 Apr 2023Short interest and volume change

    had 2.3M shares sold short in the 31 Mar 2023 report, 1.6× the same report last year.

    Same report last year: 1.5M; its normal report is 1.0M.

    See the evidence
    This period
    2.3M (the 31 Mar 2023 report)
    Normal report (median of 24 earlier)
    1.0M
    Typical spread (median absolute deviation)
    129K
    How far from its usual level
    +6.5
    Same report last year
    1.5M
    History used
    1,918 days
    2022-03-31: 1.5M2022-04-14: 1.4M2022-04-29: 1.2M2022-05-13: 1.5M2022-05-31: 1.2M2022-06-15: 1.0M2022-06-30: 1.1M2022-07-15: 1.0M2022-07-29: 1.1M2022-08-15: 1.3M2022-08-31: 1.3M2022-09-15: 991K2022-09-30: 1.2M2022-10-14: 1.0M2022-10-31: 1.1M2022-11-15: 1.0M2022-11-30: 1.0M2022-12-15: 956K2022-12-30: 930K2023-01-13: 879K2023-01-31: 802K2023-02-15: 783K2023-02-28: 767K2023-03-15: 781K2023-03-31: 2.3M
    the 31 Mar 2023 report24 earlier reportsnormal: 1.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 20 Oct 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  25. 20 Oct 2022Filings record

    Director or officer change

  26. 20 Oct 2022Filings record

    A major agreement ended

  27. 29 Apr 2022Insiders record

    Taglietti Marco (Chief Executive Officer) bought 75,000 shares of SCYX ($225,000) (dated 28 Apr 2022)

  28. 29 Apr 2022Insiders record

    Sukenick Scott (General Counsel) bought 3,500 shares of SCYX ($10,500) (dated 28 Apr 2022)

  29. 8 Feb 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 8 Feb 2022Filings record

    Director or officer change

  31. 4 Nov 2021Filings record

    Director or officer change

  32. 29 Oct 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 29 Oct 2021Filings record

    Director or officer change

  34. 25 Aug 2021Short interest and volume change

    had 3.6M shares sold short in the 13 Aug 2021 report, 19× the same report last year.

    Same report last year: 186K; its normal report is 720K.

    See the evidence
    This period
    3.6M (the 13 Aug 2021 report)
    Normal report (median of 24 earlier)
    720K
    Typical spread (median absolute deviation)
    525K
    How far from its usual level
    +3.7
    Same report last year
    186K
    History used
    1,323 days
    2020-08-14: 186K2020-08-31: 139K2020-09-15: 159K2020-09-30: 140K2020-10-15: 133K2020-10-30: 211K2020-11-13: 203K2020-11-30: 234K2020-12-15: 357K2020-12-31: 617K2021-01-15: 330K2021-01-29: 650K2021-02-12: 789K2021-02-26: 1.1M2021-03-15: 1.2M2021-03-31: 1.5M2021-04-15: 1.3M2021-04-30: 1.1M2021-05-14: 1.1M2021-05-28: 2.0M2021-06-15: 3.6M2021-06-30: 3.8M2021-07-15: 3.7M2021-07-30: 3.7M2021-08-13: 3.6M
    the 13 Aug 2021 report24 earlier reportsnormal: 720K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 11 Aug 2021Short interest and volume change

    had 3.7M shares sold short in the 30 Jul 2021 report, 19× the same report last year.

    Same report last year: 193K; its normal report is 634K.

    See the evidence
    This period
    3.7M (the 30 Jul 2021 report)
    Normal report (median of 24 earlier)
    634K
    Typical spread (median absolute deviation)
    474K
    How far from its usual level
    +4.3
    Same report last year
    193K
    History used
    1,309 days
    2020-07-31: 193K2020-08-14: 186K2020-08-31: 139K2020-09-15: 159K2020-09-30: 140K2020-10-15: 133K2020-10-30: 211K2020-11-13: 203K2020-11-30: 234K2020-12-15: 357K2020-12-31: 617K2021-01-15: 330K2021-01-29: 650K2021-02-12: 789K2021-02-26: 1.1M2021-03-15: 1.2M2021-03-31: 1.5M2021-04-15: 1.3M2021-04-30: 1.1M2021-05-14: 1.1M2021-05-28: 2.0M2021-06-15: 3.6M2021-06-30: 3.8M2021-07-15: 3.7M2021-07-30: 3.7M
    the 30 Jul 2021 report24 earlier reportsnormal: 634K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 27 Jul 2021Short interest and volume change

    had 3.7M shares sold short in the 15 Jul 2021 report, 2.6× the same report last year.

    Same report last year: 1.4M; its normal report is 634K.

    See the evidence
    This period
    3.7M (the 15 Jul 2021 report)
    Normal report (median of 24 earlier)
    634K
    Typical spread (median absolute deviation)
    474K
    How far from its usual level
    +4.4
    Same report last year
    1.4M
    History used
    1,294 days
    2020-07-15: 1.4M2020-07-31: 193K2020-08-14: 186K2020-08-31: 139K2020-09-15: 159K2020-09-30: 140K2020-10-15: 133K2020-10-30: 211K2020-11-13: 203K2020-11-30: 234K2020-12-15: 357K2020-12-31: 617K2021-01-15: 330K2021-01-29: 650K2021-02-12: 789K2021-02-26: 1.1M2021-03-15: 1.2M2021-03-31: 1.5M2021-04-15: 1.3M2021-04-30: 1.1M2021-05-14: 1.1M2021-05-28: 2.0M2021-06-15: 3.6M2021-06-30: 3.8M2021-07-15: 3.7M
    the 15 Jul 2021 report24 earlier reportsnormal: 634K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 13 Jul 2021Short interest and volume change

    had 3.8M shares sold short in the 30 Jun 2021 report, 2.3× the same report last year.

    Same report last year: 1.6M; its normal report is 634K.

    See the evidence
    This period
    3.8M (the 30 Jun 2021 report)
    Normal report (median of 24 earlier)
    634K
    Typical spread (median absolute deviation)
    474K
    How far from its usual level
    +4.5
    Same report last year
    1.6M
    History used
    1,279 days
    2020-06-30: 1.6M2020-07-15: 1.4M2020-07-31: 193K2020-08-14: 186K2020-08-31: 139K2020-09-15: 159K2020-09-30: 140K2020-10-15: 133K2020-10-30: 211K2020-11-13: 203K2020-11-30: 234K2020-12-15: 357K2020-12-31: 617K2021-01-15: 330K2021-01-29: 650K2021-02-12: 789K2021-02-26: 1.1M2021-03-15: 1.2M2021-03-31: 1.5M2021-04-15: 1.3M2021-04-30: 1.1M2021-05-14: 1.1M2021-05-28: 2.0M2021-06-15: 3.6M2021-06-30: 3.8M
    the 30 Jun 2021 report24 earlier reportsnormal: 634K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 26 Jun 2021Short interest and volume change

    had 3.6M shares sold short in the 15 Jun 2021 report, 2.1× the same report last year.

    Same report last year: 1.7M; its normal report is 634K.

    See the evidence
    This period
    3.6M (the 15 Jun 2021 report)
    Normal report (median of 24 earlier)
    634K
    Typical spread (median absolute deviation)
    474K
    How far from its usual level
    +4.3
    Same report last year
    1.7M
    History used
    1,264 days
    2020-06-15: 1.7M2020-06-30: 1.6M2020-07-15: 1.4M2020-07-31: 193K2020-08-14: 186K2020-08-31: 139K2020-09-15: 159K2020-09-30: 140K2020-10-15: 133K2020-10-30: 211K2020-11-13: 203K2020-11-30: 234K2020-12-15: 357K2020-12-31: 617K2021-01-15: 330K2021-01-29: 650K2021-02-12: 789K2021-02-26: 1.1M2021-03-15: 1.2M2021-03-31: 1.5M2021-04-15: 1.3M2021-04-30: 1.1M2021-05-14: 1.1M2021-05-28: 2.0M2021-06-15: 3.6M
    the 15 Jun 2021 report24 earlier reportsnormal: 634K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 18 May 2021Financials change

    reported revenue of $12.1M for the quarter ended 31 Mar 2021, against none in the same quarter last year.

    See the evidence
    This period
    $12.1M (the quarter ended 31 Mar 2021)
    Normal quarter (median of 8 earlier)
    $0
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +12.1
    Same quarter last year
    $0
    History used
    2,922 days
    2018-12-31: $64K2019-03-31: $64K2019-06-30: $57K2019-09-30: $02020-03-31: $02020-06-30: $02020-09-30: $02020-12-31: $02021-03-31: $12.1M
    the quarter ended 31 Mar 20218 earlier quartersnormal: $0

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  40. 24 Dec 2020Insiders change

    had 9 insiders buy $450K of its shares on the open market within 30 days (9 filings).

    Who bought: Sukenick Scott, Macdonald Guy, Angulo Gonzalez David, Taglietti Marco and 4 more.

    See the evidence (9 source records)
    Independent buyers
    9
    Purchase filings (Form 4, code P)
    9
    Total bought
    $450K
    Window
    24 Nov 2020 to 24 Dec 2020
    • Sukenick Scott (General Counsel) bought 1,600 shares of SCYX ($10,000)dated 23 Dec 2020, public 24 Dec 2020
    • Macdonald Guy (director) bought 8,000 shares of SCYX ($50,000)dated 23 Dec 2020, public 24 Dec 2020
    • Angulo Gonzalez David (Chief Medical Officer) bought 1,600 shares of SCYX ($10,000)dated 23 Dec 2020, public 24 Dec 2020
    • Taglietti Marco (Chief Executive Officer) bought 40,000 shares of SCYX ($250,000)dated 23 Dec 2020, public 24 Dec 2020
    • Francois Eric (Chief Financial Officer) bought 600 shares of SCYX ($3,750)dated 23 Dec 2020, public 24 Dec 2020
    • Tinmouth Brian Philippe (director) bought 8,000 shares of SCYX ($50,000)dated 23 Dec 2020, public 24 Dec 2020
    • (director) bought 3,200 shares of SCYX ($20,000)dated 23 Dec 2020, public 24 Dec 2020
    • ANIDO ARMANDO (director) bought 5,000 shares of SCYX ($31,250)dated 23 Dec 2020, public 24 Dec 2020
    • GILMAN STEVEN C (director) bought 4,000 shares of SCYX ($25,000)dated 23 Dec 2020, public 24 Dec 2020

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Showing the newest 40 of 107 entries; narrow the window or the kind of data to see older ones.

Not listed: 87 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001178253
Ticker
SCYX
Domain
scynexis.com
Hq location
NJ|JERSEY CITY|07302 (1 unverified)
Name
SCYNEXIS, Inc.
Uei
H6PSJYEW3DT9
  • SEC Form 13F institutional holdings450 data points30 Jun 2014 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)108 records7 Mar 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)838 data points31 Dec 2012 to 1 Nov 2026
  • SEC Form 4 insider transactions51 records, 120 data points20 May 2016 to 2 Apr 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards1 record, 15 data points29 May 2008 to 25 Sep 2026